Mike Bruninghaus is an experienced quality engineering professional currently serving as Associate Director of Quality Engineering Validation at CRISPR Therapeutics since May 2021, focusing on QA program ownership for deviation investigation activities in GxP operations. Prior to this role, Mike spent over 14 years at Sanofi Genzyme, where responsibilities included managing computer systems validation, overseeing the implementation of electronic batch record systems, and leading quality reviews for manufacturing and laboratory operations. Mike holds a Bachelor of Science in Biotechnology from Worcester Polytechnic Institute, earned in 2007.